Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Preapproval Inspections: Industry Urges FDA Transition To “For Cause”

Executive Summary

FDA should consider moving to "for cause" preapproval inspections as part of its quality systems initiative, drug manufacturers told FDA at the Product Quality Research Institute/FDA conference in Washington, D.C. April 24

You may also be interested in...



GMP Dispute Resolution Draft Guidance To Issue In Next Few Months

FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections

GMP Dispute Resolution Draft Guidance To Issue In Next Few Months

FDA expects to issue a draft guidance in the coming months on a formal dispute resolution process for scientific and technical issues that arise during inspections

BIO Petition Opposes Generic Insulin, HGH; Asks FDA To Open Public Debate

The Biotechnology Industry Organization is asking FDA to initiate a public comment process on generic biologics before it moves forward in creating approval pathways for generic therapeutic proteins

Related Content

UsernamePublicRestriction

Register

PS041745

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel